Concepedia

Matthias Broekema

MB

Statistics

Publications

8

Citations

274

H-Index

8

Active since

1998

Affiliations

Radboud University Nijmegen(Current)

Bristol-Myers Squibb (United States)

Radboud University Medical Center

Matthias Broekema is an author at Radboud University Nijmegen specializing in pharmacology, medicine, and drug discovery.

Publications per year

1998–2017

8

Publications

8

Evaluation of LMI1195, a Novel <sup>18</sup> F-Labeled Cardiac Neuronal PET Imaging Agent, in Cells and Animal Models

Ming Yu, J Bozek, Melanie Lamoy et al. · Circulation Cardiovascular Imaging · 2011 · 109 citations · Full text

Medicine, Nuclear Medicine, Pharmacology +15

Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119

Dean A. Wacker, Ying Wang, Matthias Broekema et al. · Journal of Medicinal Chemistry · 2014 · 46 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Tweezers with Different Bite: Increasing the Affinity of Synthetic Receptors by Varying the Hinge Part

Dennis W. P. M. Löwik, Melanie Weingarten, Matthias Broekema et al. · Angewandte Chemie International Edition · 1998 · 39 citations

Pharmacy, Biomolecular Engineering, Medicinal Chemistry +17

Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.

Frank G. van Schaijk, Matthias Broekema, Egbert Oosterwijk et al. · PubMed · 2005 · 21 citations

Medicine, Nuclear Medicine, Oncology +17

Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT<sub>2C</sub>Receptor Agonists

Joseph Carpenter, Ying Wang, Gang Wu et al. · Journal of Medicinal Chemistry · 2017 · 17 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 8